Category Archives: Regenerative Medicine

NEW YORK, Aug. 16, 2017 /PRNewswire/ -- Factors driving the growth of this market include the increasing number of genomics research activities for studying diseases; advances in biobanking and the growing trend of conserving cord blood stem cells of newborns; government & private funding to support regenerative medicine research, and the growing need for cost-effective drug discovery and development. On the other hand, the growth of this market is hindered to some extent due to the high cost of automation and issues related to biospecimen sample procurement.

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

"Automated storage is expected to register the highest CAGR during the forecast period" The biobanking market is classified by storage type into manual and automated storage. The automated storage type segment is expected to grow at a higher rate during the forecast period. This is attributed to launch of new and advanced automated storage equipment and increasing demand for the quality storage of samples.

"Regenerative medicine to dominate the market during the forecast period"The biobanking market is segmented based on applications regenerative medicine, life science research, and clinical research. In 2017, the regenerative medicine segment is expected to command the largest share and is also estimated to grow at the fastest rate as compared to other segments. This can be attributed to increasing research activities in the field of regenerative medicine and rising demand for well-annotated and quality biosamples for research.

"Asia-Pacific is estimated to grow at the highest CAGR during the forecast period" Geographically, the biobanking market is dominated by North America, followed by Europe. The Asia-Pacific region is estimated to grow at the fastest rate which can be attributed to the large population in China and India, increasing research in regenerative medicine, and improving life sciences research infrastructure in the region.

The primary interviews conducted for this report can be categorized as follows:

The key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.).

Study Coverage:The report analyses the biobanking market by product and service, sample type, storage type, application and regions. Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market.

Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the type, products, applications, end users, and regions.

Key benefits of buying the Report:This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

Contact Clare: rel="nofollow">clare@reportlinker.comUS:(339) 368 6001 Intl:+1 339 368 6001

View original content:http://www.prnewswire.com/news-releases/biobanking-market-by-product-and-serviceequipment-consumables-services-software-sample-type-blood-products-human-tissues-cell-lines-nucleic-acids-application-regenerative-medicine-life-science-clinical-research---g-300505662.html

SOURCE Reportlinker

More here:
Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood ... - Markets Insider

The field is called regenerative medicine, technology that shows promise of repairing or replacing human organs with new ones, healing injuries without surgery and, someday, replacing cartilage lost to osteoarthritis.

New Hampshire could become one of the centers of the new industry and become the next Silicon Valley, says Manchester inventor Dean Kamen. The governor and Legislature, however, arent doing what they need to make the potential economic and intellectual boom more likely.

Sever the spinal chord of a zebra fish, an aquarium standby, and it will regrow in a couple of weeks. Remove a limb from a salamander, and it will grow another one indistinguishable from the first. And even some humans, especially when young, can regrow a new fingertip and fingernail on a digit severed above its last joint. Medical science is moving ever closer to performing such wonders.

3-D bioprinters that use biologic materials instead of printer ink are already printing replacement human skin. A University of Connecticut scientist and surgeon believes it will be possible to regenerate human knees sometime in the next decade and regrow human limbs by 2030.

At Ohio State University, a team has succeeded in using genetic material contained in a tiny microchip attached to skin and, with a tiny, Frankenstein-like zap of electricity, reprogram skin cells to produce other types of human cells. Turn a skin cell into say, a vascular system cell, and it will migrate to the site of a wound, spur healing and restore blood flow. Convert skin cells to brain cells and, with a few more steps, it could help stroke victims recover. The technologys potential is enormous.

Kamen created the portable insulin pump, and he and his team at DEKA Research in Manchesters millyard produced the Segway human transporter, a device that provides clean water in places that lack it, an external combustion engine that will soon heat and power part of the states mental hospital, and other inventions. Their track record helped Kamen and DEKA beat out plenty of other applicants to win $80 million in federal funds to found ARMI, the Advanced Regenerative Manufacturing Institute in Manchester. Total funding is now just shy of $300 million.

The governments aim is to spur technologies that could be used to treat injured soldiers but whats learned could aid everyone and make New Hampshire a mecca for scientists, production facilities, pharmaceutical companies and more. DEKA will not create the new technologies but use its inventing and engineering expertise to help companies scale up and speed up regenerative medicine technologies so they can be brought to the market more quickly at an affordable cost.

The states university system has partnered with DEKA to train students who will one day work in the biotech field. The educational infrastructure is in place, but its handicapped by the states sorry funding of higher education. New Hampshire regularly ranks last or next to last in state support and its students carry the most debt of any in the nation.

To make New Hampshire the biotech mecca Kamen envisions will require lawmakers to better fund higher education, support the regenerative manufacturing institute and make housing available. A high-tech company that wants to come to New Hampshire cant do so if its workers cant afford a home.

Regenerative medicine is expected to become a massive economic engine, one that will create jobs and improve lives while lowering health care costs. The Legislature should be doing all it can to make sure that at least some of that engine is designed and made in New Hampshire.

Continued here:
Editorial: The growth of regenerative medicine - Concord Monitor

Scientists are making use of discarded animal organs by turning them into origami but its more than just an art project.

A team of researchers at Northwestern University created the paper cranes to demonstrate the flexibility and malleability of their latest breakthrough: a tissue paper that has the potential to heal wounds, prevent scarring and help hormone production in cancer patients.

This new class of biomaterials has potential for tissue engineering and regenerative medicine as well as drug discovery and therapeutics, Ramille Shah, one of the team members, told Northwestern.edu. Its versatile and surgically friendly.

The tissue paper is a blend of proteins from animal organs that, when wet, can be folded, rolled, cut, flattened, balled, ripped and even crafted into tiny birds. It can also be frozen for later use, making it even more practical.

In one of the first lab tests, the team successfully grew hormone-secreting follicles in a culture using a paper made from a cow ovary. Their findings were recently published in Advanced Functional Materials.

And as with many scientific discoveries, the team at Northwestern stumbled upon the new material as an accident.

The scientists were researching 3D-printed mice ovaries when one of the team members spilled the hydrogel-based gelatin ink used in creating the ovaries. The ink pooled into a dry sheet that ended up being surprisingly strong.

The light bulb went on in my head, Adam Jakus, another one of the team members, told Northwestern.edu. I knew right then I could make large amounts of bioactive materials from other organs.

Since then, the researchers have been collecting scrap pig and cow organs from a local butcher and using them to further test out the regenerative tissue paper.

Breaking down everything from animal uteruses to kidneys to muscles to hearts, the team extracts the structural proteins which give an organ its form then dries them out and combines it was a polymer, or resin, which generates the thin, paper structure.

The final product is basically a papier-mch-like sheet of proteins that can retain the biochemicals needed to regenerate a sick or injured piece of tissue, like a human liver, or skin laceration.

Though a lot more research is needed, the material could one day be used to accelerate healing after surgery and help treat hormone deficiencies in cancer patients. The researchers also found it can support human stem cell growth.

It is really amazing that meat and animal by-products like a kidney, liver, heart and uterus can be transformed into paper-like biomaterials that can potentially regenerate and restore function to tissues and organs, Jakus said. Ill never look at a steak or pork tenderloin the same way again.

Link:
'Origami organs' could be the future of regenerative medicine - New York Post

The chip has not been tested in humans, but it has been used to heal wounds in mice. Wexner Medical Center/The Ohio State University hide caption

The chip has not been tested in humans, but it has been used to heal wounds in mice.

Scientists have created an electronic wafer that reprogrammed damaged skin cells on a mouse's leg to grow new blood vessels and help a wound heal.

One day, creator Chandan Sen hopes, it could be used to be used to treat wounds on humans. But that day is a long way off as are many other regeneration technologies in the works. Like Sen, some scientists have begun trying to directly reprogram one cell type into another for healing, while others are attempting to build organs or tissues from stem cells and organ-shaped scaffolding.

But other scientists have greeted Sen's mouse experiment, published in Nature Nanotechnology on Monday, with extreme skepticism. "My impression is that there's a lot of hyperbole here," says Sean Morrison, a stem cell researcher at the University of Texas Southwestern Medical Center. "The idea you can [reprogram] a limited number of cells in the skin and improve blood flow to an entire limb I think it's a pretty fantastic claim. I find it hard to believe."

When the device is placed on live skin and activated, it sends a small electrical pulse onto the skin cells' membrane, which opens a tiny window on the cell surface. "It's about 2 percent of the cell membrane," says Sen, who is a researcher in regenerative medicine at Ohio State University. Then, using a microscopic chute, the chip shoots new genetic code through that window and into the cell where it can begin reprogramming the cell for a new fate.

Sen says the whole process takes less than 0.1 seconds and can reprogram the cells resting underneath the device, which is about the size of a big toenail. The best part is that it's able to successfully deliver its genetic payload almost 100 percent of the time, he says. "No other gene delivery technique can deliver over 98 percent efficiency. That is our triumph."

Chandan Sen, a researcher at Ohio State University, holds a chip his lab created that has reprogrammed cells in mice. Wexner Medical Center/The Ohio State University hide caption

Chandan Sen, a researcher at Ohio State University, holds a chip his lab created that has reprogrammed cells in mice.

To test the device's healing capabilities, Sen and his colleagues took a few mice with damaged leg arteries and placed the chip on the skin near the damaged artery. That reprogrammed a centimeter or two of skin to turn into blood vessel cells. Sen says the cells that received the reprogramming genes actually started replicating the reprogramming code that the researchers originally inserted in the chip, repackaging it and sending it out to other nearby cells. And that initiated the growth of a new network of blood vessels in the leg that replaced the function of the original, damaged artery, the researchers say. "Not only did we make new cells, but those cells reorganized to make functional blood vessels that plumb with the existing vasculature and carry blood," Sen says. That was enough for the leg to fully recover. Injured mice that didn't get the chip never healed.

When the researchers used the chip on healthy legs, no new blood vessels formed. Sen says because injured mouse legs were was able to incorporate the chip's reprogramming code into the ongoing attempt to heal.

That idea hasn't quite been accepted by other researchers, however. "It's just a hand waving argument," Morrison says. "It could be true, but there's no evidence that reprogramming works differently in an injured tissue versus a non-injured tissue."

What's more, the role of exosomes, the vesicles that supposedly transmit the reprogramming command to other cells, has been contentious in medical science. "There are all manners of claims of these vesicles. It's not clear what these things are, and if it's a real biological process or if it's debris," Morrison says. "In my lab, we would want to do a lot more characterization of these exosomes before we make any claims like this."

Sen says that the theory that introduced reprogramming code from the chip or any other gene delivery method does need more work, but he isn't deterred by the criticism. "This clearly is a new conceptual development, and skepticism is understandable," he says. But he is steadfast in his confidence about the role of reprogrammed exosomes. When the researchers extracted the vesicles and injected them into skin cells in the lab, Sen says those cells converted into blood vessel cells in the petri dish. "I believe this is definitive evidence supporting that [these exosomes] may induce cell conversion."

Even if the device works as well as Sen and his colleagues hope it does, they only tested it on mice. Repairing deeper injuries, like vital organ damage, would also require inserting the chip into the body to reach the wound site. It has a long way to go before it can ever be considered for use on humans. Right now, scientists can only directly reprogram adult cells into a limited selection of other cell types like muscle, neurons and blood vessel cells. It'll be many years before scientists understand how to reprogram one cell type to become part of any of our other, many tissues.

Still, Morrison says the chip is an interesting bit of technology. "It's a cool idea, being able to release [genetic code] through nano channels," he says. "There may be applications where that's advantageous in some way in the future."

Go here to see the original:
A Chip That Reprograms Cells Helps Healing, At Least In Mice - NPR

Ohio State University researchers are calling their latest development a breakthrough in regenerative medicine.

Mike Foley has details.

Researchers describe the technology, known as Tissue Nanotransfection (TNT), as an extension of gene therapy. The difference comes in the delivery of the genetic material into cells. Whereas gene therapy involves an injection or an IV, Tissue Nanotransfection takes a nanochip loaded with a specific genetic code or certain proteins and uses a small electrical current to create channels for the DNA or RNA to take root. Dr. Chandan Sen directs the Center for Regenerative Medicine and Cell-Based Therapies at Ohio States Wexner Medical Center and co-led the study. He says the technology may be used to repair injured tissue or restore function of aging tissue, including organs, blood vessels and nerve cells.

This process only takes less than a second, and is not invasive. The chip does not stay with you, and the reprogramming of the cell starts. In many cases, in seven days you start seeing changes and these changes, to our pleasant surprise, persist. Our technology is not just limited to be used on the skin. It can be used on other tissues within the body or outside the body.

In the study, researchers applied the chip to the injured legs of mice that had little to no blood flow. They reprogrammed the skin cells to become vascular cells, and within a week noticed the transformation. By the second week, active blood vessels had formed, and by the third week, researchers say the legs of the mice were saved with no other form of treatment. Results of the study are published in the journal Nature Nanotechnology. Because the technique uses a patients own cells and does not rely on medication, researchers expect to test the technology in people next year.

Follow this link:
OSU Researchers Report Breakthrough In Regenerative Medicine - WCBE 90.5 FM

Regenerative medicine is the science of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal form and function. This broadly encompasses the use of cells, tissues, drugs, synthetic biomaterials, and devices to help patients heal more effectively from trauma, cancer therapy, other disease processes, and birth anomalies. Regenerative medicine therapies can have goals of both healing damaged tissues and forming new tissue.

While many clinicians and scientists across all fields of medicine have been involved in regenerative medicine research and clinical advances over the last two decades, plastic surgeons have been especially instrumental in moving new therapies into the clinical arena and having a leadership role in new scientific discoveries.

Areas of ongoing research and clinical care:

Burn care: Plastic surgeons have been pioneers in the use of protein scaffolds to generate the dermal layer, or innermost layer of the skin, following burn injury.

Nerve regeneration: Plastic surgeons, in the practice of hand and upper extremity surgery, as well as lower extremity surgery, are forging new paths in the science of regenerating nerves and restoring optimal function after nerve injury. These therapies involve the use of special growth factors to stimulate nerve healing, as well as special biomaterials to serve as guides to direct the growth of nerve fibers.

Breast reconstruction: Breast reconstruction is a vital part of cancer therapy for many women. Plastic surgeons are achieving better outcomes through the use of decellularized tissue scaffolds to regenerate new tissue layers over implants in breast cancer survivors.

Wound care: Complex wounds that are difficult to heal represent a major focus for tissue engineering and regenerative medicine strategies. Skin substitutes, composed of living cells grown in a laboratory, are used to heal these types of wounds. Additionally, growth factors are being explored for improving wound healing. One of the most significant breakthroughs in regenerative therapy for wound healing has been the use of negative pressure devices. Discovered by a plastic surgeon, these devices use negative pressure and micro-mechanical forces to stimulate wound healing.

Fat grafting and adipose stem cell therapy: A significant advance in surgical regenerative medicine has been the development and refinement of techniques to transfer fat tissue in a minimally invasive manner. This allows the regeneration of fat tissue in other parts of the body, using a patient's own extra fat tissue. This technique is revolutionizing many reconstructive procedures, including breast reconstruction. Importantly, fat tissue is an important source of adult mesenchymal stem cells. Discovered by plastic surgeons, adipose derived stem cells, are easy to isolate from fat tissue, and hold tremendous promise for treating many disorders across the body.

Scar treatment: Plastic surgeons are experts in the biology of scar formation and the molecular signals that impact healing. Regenerative therapies are being developed using energy-based devices, such as laser and intense pulsed light, to improve the healing of scars.

Hand and face transplantation: The ultimate in "Tissue replacement therapy," hand and face transplantation represents a life-restoring therapy for patients with severe trauma or other disease processes that result in loss of the hands or face. Most people aren't aware of this fact, but the very first successful human organ transplant was performed by a plastic surgeon. Dr. Joseph Murray performed the first kidney transplant in 1954. Plastic surgeons have been building up on his legacy in developing this new field of hand and face transplantation. This field also blends elements of cell therapy in order to control the immune response and reduce the need for toxic immunosuppressive drugs.

Bioprosthetic interfaces connecting humans and machine: This very interesting area of regenerative practice is directed at methods of connecting severed nerve endings with powered artificial limbs. This often involves "rerouting" the severed nerve endings to different muscles so that sensors over the skin can detect the signals and transmit them to a computer that controls the artificial limb.

Bone regeneration: For patients suffering extensive face or a limb trauma, large segments of bone may be missing. Plastic surgeons are using calcium based scaffolds and biomaterials derived from bone to form new bone tissue for reconstructive purposes.

"Custom made tissue flaps." For deformities that involve complex structures such as a major part of the nose, plastic surgeons are engineering new replacement parts at another site on the body. In a process called "flap prefabrication," the structure is assembled using tissue grafts and then transferred to the deformity after healing.

Generation of new skin by tissue expansion: Another technique pioneered by plastic surgeons is the use of gradual expansion of implanted balloon devices to generate new skin tissue that can cover a deformity. This technique is revolutionizing breast reconstruction and the treatment of many birth anomalies.

See the article here:
Regenerative Medicine | The Future of Plastic Surgery ...

Regenerative medicine is a branch of translational research[1] in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function".[2] This field holds the promise of engineering damaged tissues and organs by stimulating the body's own repair mechanisms to functionally heal previously irreparable tissues or organs.[3]

Regenerative medicine also includes the possibility of growing tissues and organs in the laboratory and implanting them when the body cannot heal itself. If a regenerated organ's cells would be derived from the patient's own tissue or cells, this would potentially solve the problem of the shortage of organs available for donation, and the problem of organ transplant rejection.[4][5][6]

Some of the biomedical approaches within the field of regenerative medicine may involve the use of stem cells.[7] Examples include the injection of stem cells or progenitor cells obtained through directed differentiation (cell therapies); the induction of regeneration by biologically active molecules administered alone or as a secretion by infused cells (immunomodulation therapy); and transplantation of in vitro grown organs and tissues (tissue engineering).[8][9]

The term "regenerative medicine" was first used in a 1992 article on hospital administration by Leland Kaiser. Kaisers paper closes with a series of short paragraphs on future technologies that will impact hospitals. One paragraph had "Regenerative Medicine" as a bold print title and stated, "A new branch of medicine will develop that attempts to change the course of chronic disease and in many instances will regenerate tired and failing organ systems."[10][11]

The widespread use of the term regenerative medicine is attributed to William A. Haseltine (founder of Human Genome Sciences).[12] Haseltine was briefed on the project to isolate human embryonic stem cells and embryonic germ cells at Geron Corporation in collaboration with researchers at the University of Wisconsin-Madison and Johns Hopkins School of Medicine. He recognized that these cells' unique ability to differentiate into all the cell types of the human body (pluripotency) had the potential to develop into a new kind of regenerative therapy.[13][14] Explaining the new class of therapies that such cells could enable, he used the term "regenerative medicine" in the way that it is used today: "an approach to therapy that ... employs human genes, proteins and cells to re-grow, restore or provide mechanical replacements for tissues that have been injured by trauma, damaged by disease or worn by time" and "offers the prospect of curing diseases that cannot be treated effectively today, including those related to aging." [15] From 1995 to 1998 Michael D. West, PhD, organized and managed the research between Geron Corporation and its academic collaborators James Thomson at the University of Wisconsin-Madison and John Gearhart of Johns Hopkins University that led to the first isolation of human embryonic stem and human embryonic germ cells, respectively.[16]

Dr. Stephen Badylak, a Research Professor in the Department of Surgery and director of Tissue Engineering at the McGowan Institute for Regenerative Medicine at the University of Pittsburgh, developed a process for scraping cells from the lining of a pig's bladder, decellularizing (removing cells to leave a clean extracellular structure) the tissue and then drying it to become a sheet or a powder. This extracellular matrix powder was used to regrow the finger of Lee Spievak, who had severed half an inch of his finger after getting it caught in a propeller of a model plane.[17][18][19][dubious discuss] As of 2011, this new technology is being employed by the military on U.S. war veterans in Texas, as well as for some civilian patients. Nicknamed "pixie-dust," the powdered extracellular matrix is being used to successfully regenerate tissue lost and damaged due to traumatic injuries.[20]

In June 2008, at the Hospital Clnic de Barcelona, Professor Paolo Macchiarini and his team, of the University of Barcelona, performed the first tissue engineered trachea (wind pipe) transplantation. Adult stem cells were extracted from the patient's bone marrow, grown into a large population, and matured into cartilage cells, or chondrocytes, using an adaptive method originally devised for treating osteoarthritis. The team then seeded the newly grown chondrocytes, as well as epithileal cells, into a decellularised (free of donor cells) tracheal segment that was donated from a 51-year-old transplant donor who had died of cerebral hemorrhage. After four days of seeding, the graft was used to replace the patient's left main bronchus. After one month, a biopsy elicited local bleeding, indicating that the blood vessels had already grown back successfully.[21][22]

In 2009, the SENS Foundation was launched, with its stated aim as "the application of regenerative medicine defined to include the repair of living cells and extracellular material in situ to the diseases and disabilities of ageing." [23]

In 2012, Professor Paolo Macchiarini and his team improved upon the 2008 implant by transplanting a laboratory-made trachea seeded with the patient's own cells.[24]

On September 12, 2014, surgeons at the Institute of Biomedical Research and Innovation Hospital in Kobe, Japan, transplanted a 1.3 by 3.0 millimeter sheet of retinal pigment epithelium cells, which were differentiated from iPS cells through Directed differentiation, into an eye of an elderly woman, who suffers from age-related macular degeneration.[25]

Because a person's own (autologous) cord blood stem cells can be safely infused back into that individual without being rejected by the body's immune system and because they have unique characteristics compared to other sources of stem cells they are an increasing focus of regenerative medicine research.

The use of cord blood stem cells in treating conditions such as brain injury[26] and Type 1 Diabetes[27] is already being studied in humans, and earlier stage research is being conducted for treatments of stroke,[28][29] and hearing loss.[30]

Current estimates indicate that approximately 1 in 3 Americans could benefit from regenerative medicine.[31] With autologous (the person's own) cells, there is no risk of the immune system rejecting the cells.

Researchers are exploring the use of cord blood stem cells for a spectrum of regenerative medicine applications, including the following:

A clinical trial under way at the University of Florida is examining how an infusion of autologous cord blood stem cells into children with Type 1 diabetes will impact metabolic control over time, as compared to standard insulin treatments. Preliminary results demonstrate that an infusion of cord blood stem cell is safe and may provide some slowing of the loss of insulin production in children with type 1 diabetes.[32]

The stem cells found in a newborn's umbilical cord blood are holding great promise in cardiovascular repair. Researchers are noting several positive observations in pre-clinical animal studies. Thus far, in animal models of myocardial infarction, cord blood stem cells have shown the ability to selectively migrate to injured cardiac tissue, improve vascular function and blood flow at the site of injury, and improve overall heart function.[31]

Research has demonstrated convincing evidence in animal models that cord blood stem cells injected intravenously have the ability to migrate to the area of brain injury, alleviating mobility related symptoms.[33][34] Also, administration of human cord blood stem cells into animals with stroke was shown to significantly improve behavior by stimulating the creation of new blood vessels and neurons in the brain.[35]

This research also lends support for the pioneering clinical work at Duke University, focused on evaluating the impact of autologous cord blood infusions in children diagnosed with cerebral palsy and other forms of brain injury. This study is examining if an infusion of the child's own cord blood stem cells facilitates repair of damaged brain tissue, including many with cerebral palsy. To date, more than 100 children have participated in the experimental treatment many whose parents are reporting good progress.[36]

Another report published encouraging results in 2 toddlers with cerebral palsy where autologous cord blood infusion was combined with G-CSF.[37]

As these clinical and pre-clinical studies demonstrate, cord blood stem cells will likely be an important resource as medicine advances toward harnessing the body's own cells for treatment. The field of regenerative medicine can be expected to benefit greatly as additional cord blood stem cell applications are researched and more people have access to their own preserved cord blood. [38]

On May 17, 2012, Osiris Therapeutics announced that Canadian health regulators approved Prochymal, a drug for acute graft-versus-host disease in children who have failed to respond to steroid treatment. Prochymal is the first stem cell drug to be approved anywhere in the world for a systemic disease. Graft-versus-host disease, a potentially fatal complication from bone marrow transplant, involves the newly implanted cells attacking the patient's body.[39]

Less technical further reading

More technical further reading

Scientific Journals

med

Read more here:
Regenerative medicine - Wikipedia

This site uses cookies to improve performance. If your browser does not accept cookies, you cannot view this site.

There are many reasons why a cookie could not be set correctly. Below are the most common reasons:

This site uses cookies to improve performance by remembering that you are logged in when you go from page to page. To provide access without cookies would require the site to create a new session for every page you visit, which slows the system down to an unacceptable level.

This site stores nothing other than an automatically generated session ID in the cookie; no other information is captured.

In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a website to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it.

Read the original:
Regenerative Medicine

New Video Series - Watch Now

Scroll down to get an inside look into the lab and hear directly from our scientists about their projects aimed at helping patients with conditions such as diabetes, lung disease, hemophilia A and gastrointestinal disorders.

An International Leader in Regenerative Medicine

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies - all with the goal to cure, rather than merely treat, disease.

The Next Evolution of Medical Treatments

Regenerative medicine has been called the "next evolution of medical treatments," by the U.S. Department of Health and Human Services. With its potential to heal, this new field of science is expected to revolutionize health care. It is our mission at WFIRM to improve patients' lives by developing regenerative medicine therapies and support technologies.

"We have many challenges to meet, but are optimistic about the ability of the field to have a significant impact on human health. We believe regenerative medicine promises to be one of the most pervasive influences on public health in the modern era."-Anthony Atala, MD, Director

More:
Wake Forest Institute for Regenerative Medicine (WFIRM ...

Dr.DorisTayloris involved in both laboratory and clinical studies using cell therapy to treat disease. Almost5 million Americans are living with heart failure and more than half a million new cases are diagnosed annually. Almost 50,000 people die each year while awaiting a heart transplant and, for a decade or more, only about 2,200 heart transplants have been performed in the entire United States. The need is dwarfed by the availability of donor organs.

This is one of the reasons there is such hope placed in the promising field of regenerative medicine. The groundbreaking work of Dr. Taylor and her team has demonstrated the ability in the lab to strip organs, including the heart, of their cellular make-up leaving a decellularized "scaffold." The heartcan then be re-seeded with cells that, when supplied with blood and oxygen, regenerate the scaffold into a functioning heart. Dr. Taylor calls this using nature's platform to create a bioartificial heart.

The hope is that this research is an early step toward being able to grow a fully functional human heart in the laboratory. Dr. Taylor has demonstrated that the process works for other organs as well, such as kidney, pancreas, lung, and liver where she has already tested the same approachopening a door in the field of organ transplantation.

Continued here:
About Regenerative Medicine Research at the Texas Heart ...